CLINICAL EVALUATION OF PACATAL
Abstract
1. Pacatal is capable of eliciting therapeutic responses in chronically psychotic patients.
2. It is most efficacious for those aspects of behavior which are related to increased anxiety and least efficacious for judgment, insight, orientation, memory and affect.
3. The clinically significant side-effects are those related to the atropine-like action of Pacatal. Untreated eye complications, following prolonged administration of Pacatal, may lead to ulceration of the corneal epithelium.
4. It is recommended that any prolonged ocular disturbance as a result of Pacatal medication be treated with Neostigmine.
5. All the side-effects produced by Pacatal can be obliterated by symptomatic medication, lowering of daily dosage or discontinuation of the medication.
6. The results obtained with Pacatal are encouraging and warrant further investigation upon a prognostically better group of psychotic patients.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
